Vaxcyte is a pioneering vaccine company that is redefining the production of complex immunizations through advanced synthetic techniques, including the XpressCFᵀᴹ cell-free protein synthesis platform, which is designed to expedite the creation and delivery of high-fidelity vaccines. The company's lead candidate, VAX-24, a broad-spectrum pneumococcal conjugate vaccine, has been granted FDA Breakthrough Therapy designation, demonstrating its potential in preventing invasive pneumococcal disease. With a culture focused on eradicating or treating invasive bacterial infections, Vaxcyte is leading the industry in developing vaccines with an expanded breadth of coverage, including candidates designed to prevent Group A Strep infections and slow the progression of periodontal disease.